SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

CALABRO', Luana
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.063
NA - Nord America 1.464
EU - Europa 634
SA - Sud America 473
AF - Africa 38
Totale 4.672
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.363
SG - Singapore 1.054
BR - Brasile 385
HK - Hong Kong 336
CN - Cina 284
IT - Italia 183
VN - Vietnam 180
DE - Germania 111
ID - Indonesia 86
RU - Federazione Russa 84
GB - Regno Unito 81
MX - Messico 64
AR - Argentina 44
CA - Canada 27
IN - India 27
UA - Ucraina 27
NL - Olanda 26
ZA - Sudafrica 24
FI - Finlandia 20
BD - Bangladesh 18
FR - Francia 18
AT - Austria 17
PL - Polonia 17
EC - Ecuador 14
JP - Giappone 13
TR - Turchia 10
KR - Corea 9
SE - Svezia 9
ES - Italia 7
IQ - Iraq 7
VE - Venezuela 7
CH - Svizzera 6
LT - Lituania 6
CL - Cile 5
EG - Egitto 5
PY - Paraguay 5
SA - Arabia Saudita 5
UY - Uruguay 5
AE - Emirati Arabi Uniti 4
BO - Bolivia 4
JO - Giordania 4
PK - Pakistan 4
BE - Belgio 3
BY - Bielorussia 3
CO - Colombia 3
DZ - Algeria 3
NP - Nepal 3
PA - Panama 3
RS - Serbia 3
AL - Albania 2
BH - Bahrain 2
BN - Brunei Darussalam 2
DO - Repubblica Dominicana 2
EE - Estonia 2
IL - Israele 2
KH - Cambogia 2
KZ - Kazakistan 2
LV - Lettonia 2
MA - Marocco 2
MK - Macedonia 2
PH - Filippine 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BS - Bahamas 1
CI - Costa d'Avorio 1
CZ - Repubblica Ceca 1
GT - Guatemala 1
KE - Kenya 1
KW - Kuwait 1
LB - Libano 1
LU - Lussemburgo 1
MY - Malesia 1
NI - Nicaragua 1
PE - Perù 1
PT - Portogallo 1
QA - Qatar 1
SK - Slovacchia (Repubblica Slovacca) 1
SO - Somalia 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
YE - Yemen 1
Totale 4.672
Salva come PNG Salva come JPEG
Città #
Singapore 526
Santa Clara 407
Hong Kong 334
Ashburn 216
Beijing 83
Jakarta 72
Ho Chi Minh City 69
Mexico City 48
Los Angeles 41
Chandler 39
São Paulo 37
Chicago 35
Hanoi 33
London 28
Bologna 27
Dallas 25
Nuremberg 24
Milan 21
Munich 19
Ferrara di Monte Baldo 18
New York 18
Falkenstein 17
Hefei 17
Salt Lake City 16
Warsaw 15
Brasília 12
Denver 11
Lappeenranta 11
Moscow 11
Rio de Janeiro 11
Florence 10
Haiphong 10
Johannesburg 10
Montreal 10
Orem 10
Phoenix 10
Tokyo 10
Elk Grove Village 9
Stockholm 9
Buffalo 8
Düsseldorf 8
Shanghai 8
Vienna 8
Amsterdam 7
Biên Hòa 7
Boston 7
Chennai 7
Frankfurt am Main 7
Guayaquil 7
Hải Dương 7
San Francisco 7
Assago 6
Brooklyn 6
Buenos Aires 6
Curitiba 6
Da Nang 6
Ferrara 6
Hounslow 6
Quito 6
Santiago 6
Yongsan-gu 6
Dhaka 5
Fortaleza 5
Guarulhos 5
Houston 5
Juiz de Fora 5
Montevideo 5
New Delhi 5
Paris 5
Princeton 5
Recife 5
Sterling 5
Turku 5
Amman 4
Ankara 4
Atlanta 4
Belo Horizonte 4
Charlotte 4
Chiswick 4
Helsinki 4
Manaus 4
Manchester 4
Mountain View 4
Ottawa 4
Poplar 4
Portsmouth 4
Salvador 4
Seattle 4
Sorocaba 4
São Gonçalo 4
Tampa 4
Thái Bình 4
Asunción 3
Belgrade 3
Blumenau 3
Borgo San Lorenzo 3
Brussels 3
Cachoeirinha 3
Caldiero 3
Campina Grande 3
Totale 2.637
Salva come PNG Salva come JPEG
Nome #
Immune Checkpoint Inhibitors-Associated Myocarditis: Diagnosis, Treatment and Current Status on Rechallenge 119
A Multidisciplinary Approach to Improve the Management of Immune-Checkpoint Inhibitor-Related Pneumonitis 98
Near-Complete Response to Osimertinib for Advanced Non-Small-Cell Lung Cancer in a Pretreated Patient Bearing Rare Compound Exon 20 Mutation (S768I + V774M): A Case Report 91
A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas 89
Epigenetic Immune Remodeling of Mesothelioma Cells: A New Strategy to Improve the Efficacy of Immunotherapy 84
Peptide Receptor Radionuclide Therapy in Advanced Refractory Meningiomas: Efficacy and Toxicity in a Long Follow-up 83
T-Cell Receptor Repertoire Sequencing and Its Applications: Focus on Infectious Diseases and Cancer 78
Cancer Bio-Immunotherapy in Siena": Twelfth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 9-11, 2014 77
Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial 76
The emerging role of cancer nanotechnology in the panorama of sarcoma 73
Circulating haemopoietic and endothelial progenitor cells are decreased in COPD 71
Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival 69
Biomarkers for immune checkpoint inhibitors--authors' reply 69
Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial 68
Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach? 66
Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy 65
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study 64
"Cancer Bio-Immunotherapy in Siena": Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8-10, 2015 64
Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study 64
Challenges in lung cancer therapy during the COVID-19 pandemic 63
A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation 62
Bioimmunotherapeutic targets on angiogenetic blood vessels in solid malignancies 62
Cancer bio‑immunotherapy XVI annual NIBIT‑(Italian Network for Tumor Biotherapy) meeting, October 11–13 2018, Milan, Italy 60
COVID and Lung Cancer 60
Brief Communication PD1-related Nephrotoxicity: Optimizing Its Clinical Management Through Histopathologic Features 59
Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients. The DISTAL-2 randomized trial 58
Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy 56
CD40 expression by human melanocytic lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870.893 56
SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines 55
Prognostic and Predictive Role of Body Composition in Metastatic Neuroendocrine Tumor Patients Treated with Everolimus: A Real-World Data Analysis 54
Cancer Bio-Immunotherapy in Siena": Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17-19, 2013 53
Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non-Small-Cell Lung Cancer 53
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25 53
Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial 53
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study 51
Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2'-deoxycytidine in cutaneous melanoma: immunotherapeutic implications 50
Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study 49
Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases 49
The prognostic effects of circulating myeloid-derived suppressor cells in non-small cell lung cancer: systematic review and meta-analysis 49
Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream 49
Stability Program in Dendritic Cell Vaccines: A “Real-World” Experience in the Immuno-Gene Therapy Factory of Romagna Cancer Center 48
Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC 48
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer 48
The future of mesothelioma treatment: time to shift gear 48
Primary hepatic epithelioid hemangioendothelioma progressively responsive to Interferon-alpha: is there room for novel anti-angiogenetic treatments? 47
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study 46
Recombinant transmembrane CD59 (CD59-TM) confers complement resistance to GPI-anchored protein defective melanoma cells 46
Enforced expression of KDR receptor promotes proliferation, survival and megakaryocytic differentiation of TF1 progenitor cell line 44
Epigenetic drugs as pleiotropic agents in cancer treatment: Biomolecular aspects and clinical applications 44
L'ipersplenismo: Attualità e prospettive [Hypersplenism: Current status and perspectives] 43
Lymphocytes from patients with early stage of B-cell chronic lymphocytic leukaemia and long survival synthesize decorin 43
Italian cohort of nivolumab Expanded Access Programme (EAP): efficacy and safety data from a real-world population 42
Ipilimumab experience in heavily pre-treated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy) 42
Methimazole-induced agranulocytosis and quick recovery with G-CSF: case report 42
Differential levels of solubile Endoglin (CD105) in myeloid malignancies 42
Increased concentration of circulating acid glycosaminoglycans in chronic lymphocytic leukemia and essential thrombocytaemia 42
Efficacy and Safety of Chemotherapy after Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer 41
Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012 41
Markers of endothelial and platelet status in patients with essential thrombocytemia and polycythemia vera 41
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme 40
Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study 40
Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT) 40
Profilo lipidico nelle neoplasie ematologiche [Lipid profile in haematological malignancies] 40
Differential levels of solubile angiopoietin-2 and Tie-2 in patients with haematological malignancies 40
Methylation-regulated expression of cancer testis antigens in primary effusion lymphoma: immunotherapeutic implication 40
Immune-Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era 39
High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients 38
Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy 38
Immune checkpoint blockade in malignant mesothelioma: A novel therapeutic strategy against a deadly disease? 38
Epigenetic immunomodulation of hematopoietic malignancies 37
CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy? 37
Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy 37
The great need to overcome osimertinib resistance in advanced non-small cell lung cancer: from combination strategies to fourth-generation tyrosine kinase inhibitors 36
Epigenetically regulated clonal heretability of CTA expression profiles in human melanoma 36
Soluble angiogenic factors: implications for chronic myeloproliferative disorders 36
Immunophenotypic features of acute myeloid leukemias overexpressing the interleukin 3 receptor alpha chain 35
Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases 35
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial 34
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial 34
Targeting of HLA-DR molecules transduces agonistic functional signals in Cutaneous melanoma 34
Levels of solubile angiogenin in chronic myeloid malignancies: clinical implications 34
Thymosin α1 in melanoma from the clinical trial setting to the daily practice and beyond 33
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme 33
Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications 32
ICOS Expression as Immunologic Marker in Immune Activating Monoclonal Antibodies 31
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study 31
Expression and regulation of the B7-H3 receptor in human mesothelial and mesothelioma cells: a novel target for immunotherapeutic applications 30
Eighth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, October 7-9, 2010 29
Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma 29
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab 27
Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM): Results from the global, double-blind, placebo-controlled DETERMINE study 26
Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population 26
Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients 25
Goals and objectives of the Italian Network for Tumor Biotherapy (NIBIT) 21
Immune checkpoint blockade in malignant mesothelioma 20
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial 18
Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5-7, 2012 17
Immunotherapy of brain metastases: breaking a “dogma” 17
Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab 17
Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences 11
Totale 4.751
Salva come PNG Salva come JPEG
Categoria #
all - tutte 49.388
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 263
Totale 49.651
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202234 0 0 0 0 0 0 0 0 0 0 0 34
2022/2023168 5 46 3 2 48 6 5 9 22 2 10 10
2023/2024260 10 47 21 13 19 4 4 15 9 13 20 85
2024/20251.877 81 125 172 29 237 234 67 53 198 398 173 110
2025/20262.434 370 206 484 614 672 88 0 0 0 0 0 0
Totale 4.773